Interstitial Pneumonia in Patients Receiving G-CSF During Chemotherapy
Author Information
Author(s): N Niitsu, S Wk12, K Muroi, S Motomura, M Murakami, H Takeyama, A Ohsaka, A Urabe
Primary Institution: Toho University School of Medicine
Hypothesis
What are the clinical characteristics and outcomes of interstitial pneumonia in patients treated with granulocyte colony-stimulating factor (G-CSF) during chemotherapy?
Conclusion
Interstitial pneumonia is more common in older patients with hematological malignancies receiving G-CSF after pneumotoxic chemotherapy, and early diagnosis and treatment are crucial.
Supporting Evidence
- Interstitial pneumonia occurred predominantly in patients aged 60 years or older.
- It was prevalent among patients with haematological malignancies, particularly non-Hodgkin's lymphoma.
- Symptoms included dyspnoea and fever, with elevated leucocyte and LDH levels at onset.
- Chest radiographs showed granular or reticular patterns in the lungs.
- Steroid pulse therapy was effective in treating interstitial pneumonia.
Takeaway
Some older cancer patients can get a serious lung problem called interstitial pneumonia when they take a medicine called G-CSF after chemotherapy. Doctors need to check their lungs closely.
Methodology
The study reviewed cases of interstitial pneumonia in patients receiving G-CSF, focusing on symptoms, laboratory findings, and treatment outcomes.
Limitations
The study only included patients from Japan and may not represent the global population.
Participant Demographics
The average age of participants was 63 years, with 14 out of 20 being 60 years or older, and an equal number of male and female patients.
Want to read the original?
Access the complete publication on the publisher's website